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Abstract
Introduction: Most clinical trials for new antiretroviral (ARV) agents are conducted among narrowly defined adult populations.
Only after safety and efficacy have been clearly demonstrated among adults living with HIV are trials including adolescents,
children and infants conducted. This approach contributes to significant delays in the availability of optimal new ARV regimens
for infants, children and adolescents. This commentary discusses issues related to the inclusion of adolescents aged 12 to
18 years in initial HIV clinical phase 3 trials of novel antiretrovirals (ARVs) or conducting parallel phase 3 clinical trials among
adolescents.
Discussion: The absorption, metabolic and excretion or elimination pathways for drugs do not significantly differ between ado-
lescents and adults. In fact, dosing recommendations for ARVs are the same for adults and adolescents who meet the age and
weight criteria. Although conducting clinical trials among adolescents present special challenges (e.g. consenting minors and
concerns about trial completion and contraception), these challenges can be addressed to obtain high-quality trial results.
Importantly, new agents and optimized combinations have more favourable dosing schedules and side-effect profiles and are
more effective ARV agents with higher HIV drug resistance thresholds, which would be extremely beneficial to improve out-
comes among HIV-positive adolescents.
Conclusions: Adolescents may not present with significantly different pharmacokinetic characteristics from those in adults.
Including HIV-positive adolescents in phase 3 ARV clinical trials, either with adults or in specific adolescent studies conducted
in parallel, would allow adolescents to access promising, more effective treatment for HIV years earlier than with the current
stepwise approach.
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1 | INTRODUCTION
Most clinical trials for new antiretroviral drugs (ARVs) are
conducted among narrowly defined adult populations. Only
after safety and efficacy have been clearly shown in adults do
trials move to include HIV-positive children and adolescents,
significantly delaying the availability of ARVs and/or optimized
combinations for use among these groups (see Table 1). This
stepwise approach also is applied to pregnant or breast-feed-
ing women and to women of reproductive age who are not
receiving contraception. Historical rationale for this approach
mostly includes; focus on the differences between adults and
children/adolescents as they relate to drugs, developmental
variability, complexities of parental involvement and adapta-
tions required in research procedures [35].
The Paediatric Antiretroviral Working Group led by the
World Health Organization (WHO), has proposed optimizing
research approaches for children and adolescents to speed-up
the availability of ARVs and formulations for these groups [1].
Recently, the United States Food and Drug Administration (US
FDA) recommended that ARV drug trials include adolescents
(aged 12 to <18 years) in phase 3 clinical trials along with
adults, or that a separate phase 3 clinical trial among adoles-
cents be conducted in parallel [2]. Adult trials for tuberculosis
[3] and cancer treatment [4] as well as ADVANCE, a recent
clinical trial that enrolled HIV-positive participants aged
≥12 years, have shown the feasibility of including adolescents
in adult clinical trials [5].
Adolescence is a period of rapid growth and change. Physi-
cal, mental and emotional maturation changes occur as a per-
son transitions into adulthood and begins to take their own
care and decision making [6]. Adolescents are a heterogenous
population that includes individuals in various stages of emo-
tional, physical, intellectual and sexual development. Gender
differences, and environmental factors such as geographical
location, socioeconomic and sociodemographic differences,
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home environment, cultural and social support, play a mayor
role in influencing adolescents’ behaviour. Adolescence has
been widely associated with risk-taking behaviour [7]; how-
ever, it is also a period for reflection, for generating great ide-
als and building one’s personality. In this commentary, we
defined adolescents as individuals age 12 to 18 years, thus
aligning with the US FDA clinical trials recommendation.
UNAIDS 2018 estimates that 1.6 million adolescents aged 10
to 19 years are living with HIV globally. Adolescents also remain
vulnerable to acquiring new HIV infection and to have sub-opti-
mal clinical outcomes [8]. There is a paucity of HIV treatment
coverage data for adolescents living with HIV (ALHIV) and where
there is data, access and uptake of antiretroviral treatment
(ART) is often reported to be lower than among HIV-positive
adults [9]. Better-tolerated ARVs and ART regimens are needed
for ALHIV, to reduce acute and late-onset side effects, to
improve adherence and to ensure long-term viral suppression.
Expanding treatment options for adolescents is a priority, requir-
ing clinical trial generated evidence on new ARVs formulations,
dosing options and combination regimens to optimize treatment
for this vulnerable population. Not including adolescents in new
drug development trials, simplification trials or HIV treatment
failure studies will continue to widen the existing ART knowledge
gap and further disadvantage this population. This commentary
discusses benefits and challenges of including adolescents in clin-
ical phase 3 trials of ARVs or the performance of parallel adoles-
cents’ phase 3 clinical trials irrespective of the mode of HIV
acquisition, that is perinatally and sexually acquired.
2 | DISCUSSION
This section provides the rationale and justification for includ-
ing adolescents in initial adult clinical phase 3 trials of novel
ARVs and combinations or conducting parallel phase 3 clinical
trials among adolescents.
2.1 | No major pharmacokinetic differences
Absorption, hepatic metabolism and renal elimination of drugs
in infants and young children are significantly different than in
adults, but there are no major pharmacokinetic differences
between adolescents and adults [10,11]. However, bone min-
eralization, which is associated with bone metabolism and
growth may be a physiological difference between adolescents
and adults. Bone, which is a metabolic tissue, undergoes rapid
changes during adolescence and approximately 80% of adoles-
cents achieve peak bone mass by age 18 years [12]. Tenofovir
disoproxil fumarate (TDF) is the ARV most clearly related to
decreased bone mineral density in HIV-positive adults. Data
on children and youth are conflicting. Results of a 10-year fol-
low-up study in Italy indicate that a TDF-containing regimen
does not decrease the bone mineral density of HIV-positive
youths [13]. However, a longitudinal study in Brazil showed
that TDF contributes to decreased bone mineral density
among adolescents [14]. Both the US Department of Health
and Human Services (DHHS) guidelines and the WHO guideli-
nes recommend the use of TDF at the adult dose in adoles-
cents weighing >35 kg. WHO guidelines also recommend
Zidovudine and Abacavir as alternatives to TDF under special
circumstances [15-17].
2.2 | Similar dosing recommendations for
adolescents and adults
Dosing recommendations for ARVs have consistently been the
same for adults and adolescents. The DHHS guidelines recom-
mend “adult tablets” for both adults and post-pubertal adoles-
cents [11,15]. The DHHS guidelines also recommend using
most adult tablets for adolescents with a few exceptions
based on weight: for example all adult ARV tablets are
allowed for adolescents weighing ≥40 kg, some adult ARV
tablets are allowed for adolescents weighing >35 kg, and in
some cases, >25 kg [15]. The annex to the updated WHO rec-
ommendations on ARV regimens suggests the same dosing for
adults and adolescents [16].
Furthermore, the ODYSSEY trial evaluated the use of the
adult dolutegravir (DTG) tablet (50 mg) not only in adoles-
cents, but also in children weighing 20 to <40 kg. The results
showed that the adult tablets achieved appropriate pharma-
cokinetic profiles with no safety signal, allowing practical dos-
ing and rapid access to DTG [19].









Tenofovir disoproxil fumarate (Viread) 2001 300 mg OD 2010 300 mg OD for
≥12 years and
≥35 kg
Darunavir (Prezista) 2006 600 mg BID 2008 600 mg BID, for
≥40 kg
Bictegravir, only available in a fixed-dose combination tablet (Biktarvy)
Bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg
2018 50 mg OD 2019 50 mg OD, for
≥25 kg
aUnited States Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Available at http://aidsinfo.nih.gov/contentfiles/
lvguidelines/AdultandAdolescentGL.pdf. OD, once a day; BID, twice a day.
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The DHHS guidelines recommend taking the patient’s sex-
ual maturation rating (SMR) into consideration to select the
dosing for ARVs, but neither the WHO 2016 ARV guidelines
[17] or the Penta 2019 guidelines [18] even mention SMR.
SMR is only mentioned three times in the DHHS Paediatric
Guidelines Dosing Annex: dosing for efavirenz (400 mg) has
not been evaluated in patients with an SMR 3 or less; for
cobicistat/elvitegravir/emtricitabine/tenofovir (brand name,
Stribild) which is recommended for adolescents who weigh
>35 kg and have SMR 4 to 5; and TDF is recommended for
adolescents who weight >35 kg and have SMR 1 to 2. How-
ever, the guidelines do not provide different dosing recom-
mendations based on SMR. Practically, healthcare providers
consider age and/or weight (vs. SMR) to select the dosing and
to initiate ARVs per WHO or DHHS recommendations which
have already factored in SMR [15,17,34].
2.3 | Supply chain benefits
Using the same ARV formulations and dosing for adolescents
and adults can synergize programme-level supply chain man-
agement. For example new drugs approved for both adoles-
cents and adults can use an existing supply chain system,
thereby minimizing inefficiencies caused by setting up a new
supply chain system for adolescents only. Using the same dos-
ing, formulations and combinations enhance the effectiveness
and efficiency of the supply chain by minimizing the different
types of ARVs that a supply chain specialist, a healthcare pro-
vider and clients have to manage. Having different types of
ARVs for adults and adolescents can overwhelm the health-
care system and providers leading to an overloaded/inefficient
supply chain system.
Moreover, using same dosing and formulations for both
adolescents and adults streamlines ARVs treatment across
populations, facilitating the implementation of treatment
guidelines.
2.4 | Possible challenges to participation of
adolescents in clinical trials
Challenges to allowing adolescents to participate in adult clini-
cal trials include recruiting adolescents, lack of treatment
adherence and sub-optimal retention [3,21]. Obtaining
informed consent from adolescents also can be difficult
because adolescents typically are required to obtain the
approval of an adult caregiver. Adolescents also need specific
clinical trial materials that explain the trial using age-appropri-
ate language. Some clinical trials require female participants to
use contraception which may be challenging to assess and to
address possibly due to fear of disclosure [36].
2.5 | Recruiting adolescents into clinical trials
Other types of clinical trials have had challenges recruiting
adolescents. For example the participation rate of 15 to
19 year olds in a national clinical trial of cancer drugs in the
United States (1997 to 2003) was approximately half of the
corresponding rate in children aged <15 years [20]. The study
suggested that one of the reasons for low enrolment numbers
could be that adolescents exist in a “no-man’s land” between
the worlds of paediatric and adult medical oncology [21].
Enhanced collaboration between paediatric and adult special-
ists involved in caring for adolescents may improve participa-
tion in clinical trials.
Adolescent participation in HIV clinical trials is variable. The
recent ADVANCE trial enrolled participants aged ≥12 years in
South Africa; after 2 years 1053 patients had undergone ran-
domization, but only 14 patients were <19 years, despite
extensive efforts to recruit adolescents [5]. However, in the
ODYSSEY trial (PENTA 20), a randomized trial of DTG-based
ART versus the standard of care for children aged <18 years
starting first-line ART or switching to second-line ART, the
targeted number of adolescents was achieved quickly due to
higher than expected numbers of adolescent willing to partici-
pate. To increase the numbers of younger children in this trial,
the researchers had to cap the recruitment of ART-na€ıve chil-
dren who weighed ≥35 kg. Of 708 enrolled participants, 52%
were aged >12 years at trial initiation [22].
Collaboration among paediatric, adolescent and adult HIV
clinics is crucial. Protocols that not only allow adolescents to
be recruited but also identify specific adolescent HIV clinics,
could facilitate recruiting adolescents. FDA guidance advises
doing these studies in parallel or in the same protocol for
adults [2].
2.6 | Adherence to treatment and follow-up
retention in clinical trials
There are concerns that adolescents have difficulty adhering
to medication regimens, which might hinder adherence to
study drugs and attendance at follow-up visits after enrolment
[23]. The advanced FDA Paediatric HIV guidance for Industry
suggests that adolescents have lower adherence rates than
adults [2]. Nevertheless, similar treatment adherence esti-
mates have been reported both overall and by region in a
meta-analysis of adult adherence [24] and in a meta-analysis
of adolescent adherence [25]. Researchers could consider pro-
viding additional adherence support to young adolescents par-
ticipating in trials with adults since young adolescents may
have limited ability to self-care.
Some trials have shown excellent retention of children and
adolescents, for example in the BREATHER (PENTA 16) trial,
an open-label, non-inferiority trial of Efavirenz-based regimen.
The study included 199 participants from 11 countries with a
median age of 14 years (interquartile range, 12 to 18 years).
Follow-up in the trial was outstanding, with over 98% of the
clinic visits attended up to week 48 [26]. This result demon-
strates that excellent follow-up of ALHIV can be achieved.
Researchers are often concerned that including adolescents will
skew the results if included in the adult trial. To address these
concerns, researchers may analyse the adolescent and the adult
population data separately to evaluate the consequences of
possible differences. Stratification methods may also be used.
2.7 | Informed consent
Various ethical and legal complexities may arise when includ-
ing children and adolescents in clinical trials, especially when
obtaining informed consent. Clinical trials must obtain consent
from a participant with legal capacity, or from a person with
the authority to consent on the participant´s behalf. This
means that in most countries, adolescents aged <18 years
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(except emancipated minors) would need to obtain permission
from their caregivers [27] to participate in a study.
Not uncommonly, especially in low-income countries, adoles-
cents’ caregivers are grandparents or other relatives who are
not officially recognized. For example in the ARROW clinical
trial in Zimbabwe, a substantial number of potential research
participants were orphans (120/400; [30%]), and only 1/120
(0.08%) had a court-appointed guardian. The Zimbabwean
ARROW research team informed the Ethical Committee of
this challenges and how this legal requirement could poten-
tially disadvantage this group of children. The Ethical Commit-
tee waived the legal guardianship requirement but requested
that caregivers sign an informed consent document for the
children’s participation [28].
Apart from caregiver consent, adolescents younger than the
legal age of consent are required to provide an informed
assent to participate in a trial. In addition, if adolescents turn
18 years old during the trial, they have to re-consent by sign-
ing the informed consent document. For adult trial teams this
might be an additional hurdle. However, as anecdotally shown
in paediatric trials, well-trained trial teams can successfully
carry out the consent and assent processes.
Depending on country policy, some structural level adjust-
ments would be beneficial to make inclusion of adolescents
into clinical trials possible. For example in South Africa, a 12-
year-old can consent to medical treatment without caregiver
consent but cannot consent to participate in research. A stage
3 trial would benefit from including younger children for medi-
cal treatment, but other countries may not have this policy,
which makes it difficult to manage the participants of the
same age in other countries. Discussing this difficulty with key
stakeholders could help determine specific country considera-
tions and solutions.
Lastly, there are family and social-cultural considerations for
protecting adolescents from harm, especially in trials involving
highly sensitive topics for families and their communities (sex-
ual behaviour, gender identity, disclosure, etc.) [35]. Educating
Institutional Review Boards and investigators about special
regulatory protection can facilitate including adolescents in
adult phase 3 clinical trials. Institutional Review Board com-
mittees play a critical role in advancing research for all popula-
tions and discussing these issues can overcome barriers to
including adolescents in phase 3 adult clinical trials for adults.
2.8 | Designing specific clinical trial materials for
adolescents
In a discussion about conducting HIV preventive vaccine trials
with adolescents Mc-Clure et al [29] recommend designing
protocols in close consultation with local community leaders
and adolescent consultants. Using recruitment materials and
clinic sites that are friendly, attractive and accessible to ado-
lescents also can help improve participation.
Penta Foundation has supported the creation of Youth Trial
Boards in Uganda, Zimbabwe, South Africa and UK to develop a
youth-centred approach for meaningful involvement of young
patients in clinical trials and studies. ODYSSEY (PENTA 20) was
the first trial that used a Youth Trial Board [30]. This model has
been used in a few new trials (e.g. D3, BREATHER-plus, LATA) in
children, adolescents and young people led by Penta and/or the
Clinical Trials Unit at the University College of London [33].
2.9 | Contraception in adolescence
Contraception, especially for women, is usually an inclusion
criterion particularly in clinical trials for new drugs or vac-
cines. Adolescents’ reluctance to disclose whether they are
sexually active, is one of the many barriers which hinders their
access to contraception [36]. Also, there is a lack of training
among paediatricians and adult physicians on age-appropriate
sexual and reproductive health counselling [36].
In most settings, contraceptive use is governed by specific
country policies. Therefore, enrolment of adolescent girls also
depends on the country policy that dictates the age when
adolescent girls can use contraceptives. Especially in resource-
limited settings key issues pertaining to the use of contracep-
tives in adolescent girls such as cultural norms, religious
beliefs, community perspectives and stigma (for HIV and con-
traceptive use), might pose major enrolment concerns and
could be addressed during the trial planning phase [31]. Rais-
ing community awareness and education is also crucial [32].
3 | CONCLUSIONS
HIV-positive adolescents remain at a disadvantage in terms
of access to new drugs. Adolescents do not differ signifi-
cantly from adults in weight, physiology, pharmacokinetics or
adherence to treatment. Therefore, including ALHIV in initial
phase 3 clinical trials with adults or in separate parallel
studies could allow adolescents to benefit earlier from opti-
mized ART. Coordinating research efforts with key stake-
holders and sharing experiences on how to overcome
perceived and real difficulties could help promote clinical tri-
als among adolescents.
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